Should oral bisphosphonates be standard of care in women with early breast cancer?
- 1 April 2005
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 90 (3) , 315-318
- https://doi.org/10.1007/s10549-004-4259-3
Abstract
There is increasing evidence that oral clodronate has important clinical benefits in early breast cancer. Longer-term follow-up data from two out of three randomized studies have shown that adjuvant clodronate improves survival. This article outlines the results of these studies and discusses the potential role for other bisphosphonates, such as ibandronate and zoledronic acid, in the adjuvant treatment of breast cancer.Keywords
This publication has 20 references indexed in Scilit:
- Renal safety of ibandronate in patients with bone metastases from breast cancer: phase III trial resultsEuropean Journal of Cancer Supplements, 2004
- Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studiesBritish Journal of Cancer, 2004
- Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancerBMJ, 2003
- Bisphosphonates for breast cancerPublished by Wiley ,2002
- Bisphosphonates Induce Breast Cancer Cell Death In VitroJournal of Bone and Mineral Research, 2000
- Skeletal complications of malignancyCancer, 1997
- Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.Journal of Clinical Investigation, 1996
- Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.Journal of Clinical Oncology, 1995
- Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.Journal of Clinical Oncology, 1993
- Bone metastasis in breast cancerAnti-Cancer Drugs, 1992